Table 1 Eligibility criteria

Inclusion criteria

Age between 30 and 80, regardless of gender

For participants who are receiving anti-Parkinson treatment (levodopa preparations, dopamine agonists, monoamine oxidase inhibitors, catechins-o-methyl transferase (COMT) inhibitor, anticholinergic drugs, etc.), the dosage of the anti-Parkinson drug is requested to be relatively stable for at least 3 months before this clinical trial, and no plan has been made to change the existing treatment in the next 3 months

Voluntarily participate and sign informed consent

Exclusion criteria

Patients with Parkinson Syndrome (PS) or Parkinsonism-Plus syndrome (PPS)

Pregnant or lactating women, history of drug or alcohol abuse

Severe cognitive impairment (Montreal Cognitive Assessment scale (MoCA) < 20 points), active depression or psychosis and/or under antidepressant or antipsychotic medication, severe sequelae of stroke and other systemic diseases affecting the heart, lung, liver or kidney

Participating in other clinical studies or have participated in other clinical study within the previous 30 days